Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Aurobindo Pharma
  6. News
  7. Summary
    AUROPHARMA   INE406A01037


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19

10/08/2021 | 05:26pm EST
FILE PHOTO: A handout photo of an experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP

BENGALURU (Reuters) - Two Indian drugmakers have requested permission to end late-stage trials of their generic versions of Merck & Co's promising experimental oral antiviral drug molnupiravir to treat moderate COVID-19, a week after Merck said its own trial had succeeded for mild-to-moderate patients.

Merck earlier this year suspended its own development of molnupiravir as a treatment for hospitalized COVID-19 patients since many of them have reached a phase of the disease that is too late for an antiviral drug to provide much help.

The Indian companies - Aurobindo Pharma Ltd and MSN Laboratories - did not exclude hospitalized patients in designing their moderate COVID-19 trials, according to study documents, although it was not known if the trials ultimately included people in the hospital.

Merck spokesperson Melissa Moody said Merck and the Indian companies had defined "moderate" disease differently.

Merck's trials are based on U.S. Food and Drug Administration definitions, which for moderate COVID-19 describe blood oxygen levels as no lower than 93%. It defines blood oxygen levels for severe COVID-19 as 93% or lower.

The trials in India define moderate COVID-19 blood oxygen levels as 90% to 93%, according to the trial documents for the two companies.

Aurobindo and MSN are continuing to conduct studies of molnupiravir in patients with mild COVID-19 who have not been hospitalized, according to trial documents and the website of the Indian drug regulator's internal expert committee.

Merck and partner Ridgeback Biotherapeutics last week said molnupiravir had nearly halved the risk of hospitalization or death in at-risk non-hospitalized patients with mild-to-moderate COVID-19, results hailed by experts as potentially a major advance in fight against the illness.

The Indian drug regulator's committee also disclosed on its website that Aurobindo and MSN had presented interim clinical trial data for moderate COVID-19 patients and asked to end the trials.

A source with the Drug Controller General of India said the pill has not shown "significant efficacy" against moderate COVID-19, though it was having success against mild cases.

An Aurobindo spokesperson did not comment on the effectiveness of the drug in its trial. The spokesperson said the company had "faced challenges in patient recruitment at this juncture" for its trial in moderate COVID-19 patients, adding "we are evaluating the further course of action."

Aurobindo started the planned 100-patient trial of its generic version of the Merck pill against moderate COVID-19 in August, and is also running a trial that hopes to include 1,200 patients testing the pill against mild disease.

MSN did not respond to a request for comment.


Merck, whose shares closed down 1.6% at $80.63, has entered into voluntary licensing agreements with at least eight Indian drugmakers for molnupiravir, with an aim to turn the South Asian nation into a manufacturing hub for the drug to supply low- and middle-income nations.

Five of the eight Indian companies - Dr Reddy's Laboratories, Cipla, Sun Pharma, Torrent Pharmaceuticals and Emcure Pharmaceuticals - are conducting a joint trial for the antiviral drug only in mild COVID-19 patients in an outpatient setting.

The other licensed company, Hetero, in early July announced interim data from its own late-stage trial of generic molnupiravir in mild COVID-19 patients and submitted an application to regulators for its emergency use.

Hetero is separately conducting a study on moderate COVID-19 patients and has said those results will be presented at a future date.

(Reporting by Shivani Singh and Anuron Kumar Mitra in Bengaluru and Neha Arora in New Delhi, additional reporting by Deena Beasley; Editing by Caroline Humer and Bill Berkrot)

By Shivani Singh, Anuron Kumar Mitra and Neha Arora

ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AUROBINDO PHARMA 0.36% 662.6 Delayed Quote.-28.34%
CIPLA LIMITED -4.44% 928.15 Delayed Quote.18.46%
DR. REDDY'S LABORATORIES LIMITED -0.34% 4681.15 End-of-day quote.-10.05%
SUN PHARMACEUTICAL INDUSTRIES LTD. -1.09% 745.35 Delayed Quote.27.22%
TORRENT PHARMACEUTICALS LIMITED 0.31% 3043.35 End-of-day quote.8.66%
11/18Aurobindo Receives FDA Approval for Prednisone Tablets USP, 1mg
11/17Companies make progress tackling drug-resistant infections, foundation says
11/17Indian shares hit 1-week low as pharma drags, Reliance falls 2%
11/17AUROBINDO PHARMA : Ex-dividend day for interim dividend
11/09Pr-q2 fy 2021-22
11/09Earnings Presentation – Q2 FY 2021-22
11/08Aurobindo Pharma Limited Reports Earnings Results for the Second Quarter and Six Months..
10/26Novartis may divest generic unit Sandoz as price pressures mount
10/26Novartis 3Q Earnings, Sales Grow; Announces Strategic Review of Generics Division -- Up..
10/21AUROBINDO PHARMA : Receives FDA Approval for Diclofenac Potassium Capsules, 25mg
More news
Analyst Recommendations on AUROBINDO PHARMA
More recommendations
Sales 2022 244 B 3 251 M 3 251 M
Net income 2022 30 901 M 412 M 412 M
Net cash 2022 16 022 M 214 M 214 M
P/E ratio 2022 12,5x
Yield 2022 0,63%
Capitalization 387 B 5 150 M 5 162 M
EV / Sales 2022 1,52x
EV / Sales 2023 1,36x
Nbr of Employees 19 364
Free-Float 71,3%
Duration : Period :
Aurobindo Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AUROBINDO PHARMA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 660,25 INR
Average target price 866,64 INR
Spread / Average Target 31,3%
EPS Revisions
Managers and Directors
Narayanan Govindarajan Managing Director & Executive Director
Santhanam Subramanian Chief Financial Officer
Kannan Ragunathan Non-Executive Chairman
B. Adi Reddy Secretary & Compliance Officer
Avnit Bimal Singh Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-0.92%410 501
ROCHE HOLDING AG16.39%337 091
PFIZER, INC.45.97%301 579
NOVO NORDISK A/S65.17%243 741